Structure Therapeutics Inc. (NASDAQ:GPCR) Shares Purchased by Principal Financial Group Inc.

Principal Financial Group Inc. boosted its position in shares of Structure Therapeutics Inc. (NASDAQ:GPCR - Free Report) by 230.0% during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 545,359 shares of the company's stock after acquiring an additional 380,115 shares during the period. Principal Financial Group Inc. owned approximately 0.95% of Structure Therapeutics worth $23,936,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in GPCR. Geode Capital Management LLC raised its position in shares of Structure Therapeutics by 0.7% during the third quarter. Geode Capital Management LLC now owns 45,225 shares of the company's stock worth $1,985,000 after acquiring an additional 312 shares during the last quarter. Squarepoint Ops LLC increased its stake in Structure Therapeutics by 4.5% in the second quarter. Squarepoint Ops LLC now owns 14,449 shares of the company's stock valued at $567,000 after purchasing an additional 617 shares in the last quarter. Assetmark Inc. raised its holdings in Structure Therapeutics by 120.0% during the 3rd quarter. Assetmark Inc. now owns 1,318 shares of the company's stock worth $58,000 after buying an additional 719 shares during the period. Sandia Investment Management LP bought a new stake in shares of Structure Therapeutics in the second quarter valued at about $39,000. Finally, Mirae Asset Global Investments Co. Ltd. raised its position in Structure Therapeutics by 60.1% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,784 shares of the company's stock valued at $158,000 after buying an additional 1,420 shares during the last quarter. Institutional investors own 91.78% of the company's stock.

Analyst Upgrades and Downgrades

GPCR has been the subject of a number of analyst reports. JMP Securities restated a "market outperform" rating and issued a $91.00 price target on shares of Structure Therapeutics in a research note on Wednesday, December 18th. Morgan Stanley started coverage on Structure Therapeutics in a report on Monday, September 23rd. They set an "overweight" rating and a $118.00 price objective for the company. Cantor Fitzgerald reiterated an "overweight" rating and set a $65.00 target price on shares of Structure Therapeutics in a research note on Monday, September 23rd. Finally, HC Wainwright reiterated a "buy" rating and set a $80.00 target price on shares of Structure Therapeutics in a research report on Thursday, December 19th. Seven investment analysts have rated the stock with a buy rating, According to MarketBeat.com, Structure Therapeutics has an average rating of "Buy" and a consensus price target of $86.50.

Structure Therapeutics Stock Performance

Shares of Structure Therapeutics stock traded up $1.29 on Thursday, hitting $29.54. 782,285 shares of the company's stock were exchanged, compared to its average volume of 799,986. The company has a 50-day simple moving average of $34.78 and a 200-day simple moving average of $38.19. The stock has a market capitalization of $1.69 billion, a PE ratio of -39.92 and a beta of -3.41. Structure Therapeutics Inc. has a 1 year low of $26.23 and a 1 year high of $62.74.

Structure Therapeutics Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.